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OBJECTIVES The goal of this study was to evaluate whether reducing the potentially deleterious effects of
oxidative stress with the potent anti-oxidant probucol improves prognosis after myocardial
infarction (MI) in rats.
BACKGROUND Oxidative stress has been documented in patients early and late after MI, particularly when
it is associated with congestive heart failure.
METHODS Rats surviving acute MIs for 24 h (n  247) were assigned to vehicle or probucol (61 mg/kg,
daily) for four weeks, at which time cardiac hemodynamic, morphologic and molecular
measurements were done.
RESULTS In rats with large MIs, probucol improved survival (87.9%) when compared with vehicle
(50.6%) (p  0.001). Probucol also partially preserved left ventricular (LV) systolic but not
diastolic function. Probucol increased scar thickness and decreased cardiac fibrosis but did not
modify LV hypertrophy or dilation. Finally, probucol decreased cardiac oxidative stress, as
assessed by measuring cardiac malondialdehydes, and decreased the cardiac expression of the
pro-inflammatory cytokines interleukin (IL)-1 and IL-6 but did not modify fetal gene
re-expression in rats with large MIs.
CONCLUSIONS This study indicates that the anti-oxidant probucol markedly improves post-MI survival in
rats despite few demonstrable effects on cardiac remodeling or hemodynamics. Its beneficial
effects may, however, be associated with reduced cardiac fibrosis, oxidative stress and
expression of pro-inflammatory cytokines. (J Am Coll Cardiol 2002;39:148–56) © 2002 by
the American College of Cardiology
Morbidity and mortality after large myocardial infarction
(MI) remain elevated and are associated with progressive
post-MI ventricular remodeling and dysfunction (1). Why
the heart remodels and finally fails in some patients after a
large MI remains incompletely understood, but evidence
from experimental and clinical trials would suggest that
hemodynamic and neurohumoral factors are involved (1).
More recently, interest has begun to focus on more local
myocardial factors that are influenced by hemodynamic
changes and neurohumoral activation. These include pro-
inflammatory cytokines, reactive oxygen species and peptide
growth factors, which are all upregulated after MI and can
lead to further adverse ventricular remodeling and dysfunc-
tion (2).
Oxidative stress may contribute to poor post-MI prog-
nosis via numerous mechanisms, of which direct cytotoxic,
negative inotropic, cytokine stimulating and apoptotic ef-
fects are but a few (3–5). Singal et al. (6) have shown that
the occurrence of oxidative stress coincides with the appear-
ance of hemodynamic abnormalities after MI in rats (6). In
that post-MI model, therapy with the anti-oxidant vitamin
E helped prevent progressive myocardial dysfunction, a
finding that was related to the maintenance of a more
normal endogenous anti-oxidant status of the heart (7).
More recently, Kinugawa et al. (8) demonstrated that the
powerful anti-oxidant, dimethylthiourea (DMTU) started
4 h after MI preserved ventricular function, attenuated
ventricular dilation, reduced cardiac fibrosis and attenuated
the increase in myocardial matrix metalloproteinase-2 activ-
ity that normally occurs after MI. Although this is provoc-
ative in its implications, more information as to what
mechanisms are involved and whether these promising
findings lead to improved survival are necessary.
Probucol is a cholesterol-lowering agent with potent
anti-oxidant properties (9). It has been shown to prevent the
development of adriamycin cardiomyopathy and ventricular
dysfunction in rats (10). These beneficial effects of probucol
are thought to be the result of improved myocardial anti-
oxidant activity and are accompanied by a decrease in
cardiac oxidative stress (10). Whether it has beneficial
post-MI effects remains to be tested.
In this study we hypothesized that the anti-oxidant
probucol would lead to improved post-MI survival and
that this would be associated with beneficial effects on left
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ventricular (LV) remodeling and function, reduced oxi-
dative stress and reduced cardiac expression of pro-
inflammatory cytokines.
METHODS
Animal care. Male Wistar rats weighing from 200 to 250 g
were obtained from Charles Rivers Breeding Laboratories
(Saint-Constant, Quebec, Canada). All care was in accor-
dance with the “Canadian Council for Animal Care” and
the “Animal Care Committee Guidelines” of the Montreal
Heart Institute.
MI operative procedure. Myocardial infarction was in-
duced in rats by ligating the left anterior coronary artery as
described previously (11). There was a high early mortality
rate (51% within 24 h), the survivors being randomized into
different treatment groups. At the time they were eutha-
nized, rats were classified as having either a large MI, an LV
scar of 45% of the LV circumference or a scar-to-body-
weight ratio0.2 g/kg, or no or small MI, LV scar between
0% and 20% of circumference or a scar-to-body-weight
ratio between 0.0 g/kg to 0.1 g/kg (11). Other rats were not
further considered. Rats dying between 24 h and 72 h after
MI were assumed to have had a large MI, and those dying
later, but before 28 days, had morphologic studies.
Pharmacologic interventions. Rats surviving 24 h after
MI were randomized into two groups as follows: 1) vehicle
(soya bean oil); and 2) probucol (61 mg/kg/day) (10) (Fig.
1). Soya bean oil was used as the vehicle because probucol is
lipid soluble. All drugs were given by gavage. All rats were
treated for 28 to 30 days.
Long-term cardiac hemodynamic studies. After four
weeks of treatment, the rats were initially anesthetized with
3% halothane mixed with 100% O2. The halothane per-
centage was reduced to 1% 3 min before hemodynamic
recordings. Left ventricular and right ventricular (RV)
hemodynamics were measured as previously described (11).
Abbreviations and Acronyms
ANF  atrial natriuretic factor
BW  body weight
cDNA  complementary DNA
DMTU  dimethylthiourea
GAPDH  glyceraldehyde 3-phosphate dehydrogenase
HR  heart rate
IL  interleukin
LV  left ventricle or left ventricular
LVEDP  left ventricular end-diastolic pressure
LVSP  left ventricular systolic pressure
LVW  left ventricle weight
MHC  myosin heavy chain
MI  myocardial infarction
mRNA  messenger RNA
NE  norepinephrine
RV  right ventricle or right ventricular
RVSP  right ventricular systolic pressure
RVW  right ventricle weight
SkACT  skeletal actin
TNF  tumor necrosis factor
dP/dt  maximum rate of pressure rise
dP/dt  maximum rate of pressure decline
Figure 1. Flow diagram of various groups of rats according to myocardial infarction (MI) size and treatment group.
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Passive pressure-volume relationship. After completing
the cardiac hemodynamic measurements, 46 rats had their
hearts stopped in diastole by an intravenous injection of a
saturated potassium chloride solution. The passive pressure-
volume relationship of each heart was then assessed as
previously described (11).
Cardiac remodeling. Once the pressure-volume curve was
completed, the LV was filled with saline solution to a
pressure of 15 mm Hg, sealed and fixed in its distended
form in 10% formalin phosphate buffer for 24 h. Two
cross-sections were obtained at 1-mm intervals midway
between the base and the apex of the LV for morphometry
as previously described (11). The average scar thickness was
obtained directly by planimetry as well. The LV surface area
at the endocardium (cavity) and epicardium (cavity and
ventricular wall  ventricular area) were numerically
summed separately. For both cross-sectional levels, dilation
index was expressed as the ratio of LV cavity area/LV area.
Cardiac fibrosis assessment. This procedure consisted of
using samples from both cross-sections stained with Sirius
red F3BA as a 0.1% solution in saturated aqueous picric acid
as described previously (12). Collagen volume density frac-
tion was then determined by measuring the area of stained
tissue within a given field and expressing that area as a
proportion of the total area under observation. The
collagen-rich border zone of vessels was not included in the
calculations. Ten fields were analyzed in the subendocardial
layer and 10 fields in the subepicardial layer in each LV. The
collagen-rich border of the scar was not included.
Cardiac and lung weights. A total of 168 rats were used to
assess cardiac hypertrophy once the hemodynamic protocol
was completed, as previously described (11). The scarred
area was pinned on a paper, and its surface was determined
by planimetry. Each tissue was then weighed individually,
frozen in liquid nitrogen, and stored at 80°C. The lungs
were also weighed and frozen.
Plasma norepinephrine (NE) measurements. Plasma NE
was measured by methods described previously (11).
Quantification of fetal gene expression in LV myocardi-
um. Myocardial fetal gene expression, as assessed by mea-
suring messenger RNA (mRNA) for atrial natriuretic fac-
tor, beta myosin heavy chain (MHC), alpha myosin heavy
chain (MHC) and skeleton actin (skACT) was evaluated
in myocardium from the LV of six hearts from each group
and normalized for glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) expression as previously described (13).
Ribonuclease protection assay for cardiac inflammatory
cytokine panel. To determine the gene expression of cy-
tokines from the affected myocardium, ribonuclease protec-
tion assay was performed to quantitate the mRNA levels of
tumor necrosis factor (TNF)-, interleukin (IL)-1, -5 and
-6. The complementary DNA (cDNA) probes specific for
the rat target cytokines were prepared from a commercially
available kit based on known coding sequences (RiboQuant,
PharMingen; Wilmington, Delaware) according to the
manufacturer’s instructions. Specifically, the cDNA tem-
plates of the target cytokines were amplified using polymer-
ase chain reaction and labeled with 33 P-UTP (Dupont,
New England Nuclear; San Diego, California). Commer-
cially available cDNA probes for housekeeping genes L32
and GAPDH were also amplified and labeled to act as
standardization controls.
The total RNA from the myocardial samples was ex-
tracted and purified according to techniques previously
published from our laboratory (14), taking particular care to
ensure RNase-free reaction conditions.
Cardiac oxidative stress. Cardiac oxidative stress was as-
sessed by measuring cardiac aldehydes. The four groups of
cardiac aldehydes were: 1) straight chained aldehydes; 2)
branch chained aldehydes; 3) unsaturated aldehydes; and 4)
malondialdehydes. Samples were analyzed by gas chroma-
tography mass spectrometry using the previously described
method from Luo et al. (15).
Statistical analyses. All values are expressed as mean 
SEM. Results were analyzed by using a two-tailed Student
t test for unpaired data and by analysis of variance
(ANOVA) for multiple comparisons followed by a two-
sided Dunnett’s test or Student-Newman-Keuls test, when
appropriate. The pressure-volume relationships of the dif-
ferent groups were compared by repeated ANOVA mea-
surements and the interaction term for the effect of probucol
tested. Kaplan-Meier survival curves over the follow-up
period were constructed and analyzed by the generalized
Savage (Mantel-Cox) test. Gels were analyzed by densitom-
etry, and the results were presented as mean (arbitrary units)
 SEM. Statistical significance was assumed at p 0.05.
RESULTS
Survival. The total number of rats used in the study was
519. Of these, 272 died within 24 h after coronary ligation
and, thus, were excluded from the study (Fig. 2). The
remaining 247 rats were treated randomly with soya bean oil
(n  201) or probucol (n  46). Regardless of treatment
group, the survival rate of rats with sham-to-small MIs was
excellent over the four weeks of follow-up.
The early (72 h) post-MI mortality of rats with large
MIs treated with vehicle (soya bean oil) was 16.9% (26
deaths). Rats with large MIs treated with probucol had a
strong tendency toward lower post-MI (72 h) mortality
(6.1%) (2 deaths, p 0.055 vs. vehicle). The overall survival
rates (28 days) of rats with large MIs were 50.6% for vehicle
and 87.9% for probucol (vehicle vs. probucol, p  0.001)
(Fig. 2).
Hemodynamic measurements. In rats with sham-to-small
MIs, probucol treatment increased heart rate (HR), LV
systolic pressure (LVSP), LV end-diastolic pressure
(LVEDP) and maximum rate of pressure rise and decline
(LV dP/dt) compared with the vehicle group, suggesting
increased adrenergic tone (Table 1).
Vehicle rats with large MIs had a decrease in HR, LVSP,
LV dP/dt and an increase in LVEDP. This was accom-
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panied by an increase in both RV systolic and end-diastolic
pressures (RVSP and RVEDP) and in RV dP/dt. Com-
pared with vehicle rats with large MIs, probucol treatment
resulted in an increase in HR, LVSP, LVEDP and LV
dP/dt. Right ventricular hemodynamic parameters were
not modified by probucol.
Morphologic assessment. In the sham-to-small-MI
groups, probucol resulted in a slight reduction in the LV
weight/body weight (LVW/BW) ratio (Tables 2 and 3, Fig.
3). The two large-MI groups had a significant decrease in
BW, this decrease being less in the probucol group. The scar
weight and scar weight/BW ratios were similar in both
large-MI groups. Left ventricular weight/BW was reduced
only in the vehicle large-MI group. Atria weight/BW ratio
increased in both MI groups, but RV weight/BW (RVW/
BW) increased less in the probucol group, and the increase
in lung weight/BW ratio also tended to be less in the
probucol group, suggesting less pulmonary congestion.
When not corrected for BW, LVW was greater in the MI
probucol group than in the MI vehicle group, and RVW
was no longer significantly different between MI groups.
In the sham-to-small-MI group, the morphologic char-
acteristics of mid-LV cross-sections were similar in both
groups, except for cardiac fibrosis, which was less in the
probucol group. In rats with large MIs, LV endocardial and
epicardial circumferences, scar surface, cardiac fibrosis and
dilation index increased (Fig. 3, Table 3). Probucol treatment
resulted in increased scar thickness and a marked decrease in
cardiac fibrosis, compared with vehicle-treated large MIs.
Passive pressure-volume relationship. In rats with sham-
to-small MIs, pressure-volume relationships were similar
regardless of treatment group (Fig. 4). A large MI caused a
similar rightward shift of this relationship regardless of treat-
ment; no interaction with probucol was found (p  0.264).
Plasma NE four weeks after infarction. In sham-to-small
MIs, plasma NE levels were similar in the two groups:
505  62 pg/ml for vehicle and 312  91 pg/ml for
probucol. In the large-MI vehicle group, NE increased to
1,183  211 pg/ml, p  0.01, and probucol did not
significantly modify this increase (846  123 pg/ml).
Fetal gene expression 28 days after MI in the LV. In
sham-to-small MIs, expression of skACT, atrial natriuretic
Figure 2. Comparison of survival of rats with large myocardial infarctions during the study period. Survival with probucol (88%) was much better than it
was with vehicle (51%).
Table 1. Hemodynamic Monitoring Four Weeks After MI
HR
(beats/min)
RVSP
(mm Hg)
RVEDP
(mm Hg)
RV dP/dt
(mm Hg/s)
LVSP
(mm Hg)
LVEDP
(mm Hg)
LV dP/dt
(mm Hg/s)
LV dP/dt
(mm Hg/s)
Sham-to-small MI vehicle
(n  46)
386  7 25.7  0.7 0.9  0.6 1,304  45 100.6  2.1 1.9  0.8 5,015  170 4,829  178
Probucol (n  13) 426  13* 28.2  0.7 0.9  0.2 1,027  86* 123.6  3.6* 6.3  1.0* 6,104  333* 6,312  332*
Large MI vehicle
(n  46)
368  8† 45.1  1.7† 8.7  0.9† 1,459  56† 88.7  1.5† 23.4  1.1† 3,308  144† 2,453  122†
Probucol (n  29) 406  9* 44.2  2.1† 7.7  1.1† 1,458  59 104.4  1.8*† 28.3  1.5*† 4,051  156*† 3,091  134*†
*p  0.05 vs. vehicle; †p  0.05 vs. sham or small MI.
HR  heart rate; LV dp/dt  left ventricular maximum rate of pressure rise; LVEDP  left ventricular end-diastolic pressure; LVSP  left ventricular systolic pressure;
MImyocardial infarction; RVdP/dt right ventricular maximum rate of pressure rise; RVEDP right ventricular end-diastolic pressure; RVSP right ventricular systolic
pressure.
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factor (ANF) and MHC were barely detectable in LV
tissue, whereas MHC showed marked expression (Table
3). In large MIs, a five- to six-fold induction of skACT,
ANF and MHC were observed, whereas MHC
mRNA levels were reduced to about 50% regardless of
treatment. The GAPDH steady state mRNA levels served
as a control.
Cardiac inflammatory cytokine gene expression. Cardiac
expression of cytokines was similar in the two sham-to-
small-MI groups, except for IL-6, which was decreased in
the probucol group (Fig. 5). The large-MI vehicle group
had an increase only in IL-1 cardiac expression. Probucol
treatment in large MIs prevented the increase in cardiac
expression of IL-1 and reduced IL-6 levels to levels lower
than those of sham-to-small-MI controls. It also tended to
reduce the expression of IL-5 compared with the large-MI
vehicle group (p  0.12).
Cardiac oxidative stress. Myocardial oxidative stress
markers were similar in the sham-to-small-MI groups (Fig.
5). A large MI increased cardiac malondialdehydes only in
the vehicle group, this increase being prevented by probucol.
DISCUSSION
This study indicates that the anti-oxidant probucol, when
started 24 h after MI, markedly reduces both early and late
post-MI mortality in rats. This is accompanied by partial
preservation of LV systolic but not diastolic function. This
does not appear to be the result of prevention of LV dilation
or prevention of LV fetal gene expression but may be related
to reduced cardiac fibrosis, reduced cardiac oxidative stress
and reduced expression of cardiac pro-inflammatory cyto-
kines. Taken together, these results suggest that excessive
oxidative stress occurs after MI, that it is detrimental, and
that preventing it with a powerful anti-oxidant such as
probucol improves prognosis.
Probucol is a powerful anti-oxidant agent that was first
introduced in clinical practice as a cholesterol-reducing
agent. It has now been pulled off the market because it was
found to exert its cholesterol-lowering effects by reducing
the so-called good cholesterol, high-density lipoprotein, and
because it was found to prolong the QT interval in some
patients. In rats, probucol has been shown to attenuate the
development of adriamycin cardiomyopathy, a finding as-
Table 2. Heart and Lung Weight Four Weeks After MI
Sham-to-Small MI Large MI
Vehicle
(n  47)
Probucol
(n  13)
Vehicle
(n  78)
Probucol
(n  29)
BW (g) 405  5 420  8 376  4* 394  6*†
SW (g) 0.03  0.00 0.02  0.00 0.11  0.00* 0.11  0.00
SW/BW (g/kg) 0.07  0.01 0.05  0.01 0.30  0.01* 0.26  0.01*
LVW/BW (g/kg) 2.10  0.03 1.98  0.05† 1.97  0.03* 2.03  0.06
LVW (g) 0.82  0.01 0.83  0.02 0.63  0.02* 0.71  0.02*†
RVW/BW (g/kg) 0.59  0.02 0.58  0.05 1.08  0.05* 0.94  0.04*†
RVW (g) 0.24  0.01 0.25  0.01 0.41  0.02* 0.37  0.02*
AW/BW (g/kg) 0.21  0.01 0.19  0.01 0.51  0.02* 0.44  0.03*
Lung weight/BW (g/kg) 4.24  0.12 3.99  0.17 8.02  0.30* 7.20  0.41*
Lung weight (g) 1.73  0.05 1.68  0.07 3.06  0.18* 2.80  0.16*
*p  0.05 vs. sham or small MI; †p  0.05 vs. vehicle.
AW  atria weight; BW  body weight; LVW  left ventricular weight; MI  myocardial infarction; RVW  right
ventricular weight; SW  scar weight.
Table 3. Morpholigic Characteristics of Mid Left Ventricular Cross-Sections and Fetal Gene
Expression Four Weeks After MI
Sham-to-Small MI Large MI
Vehicle
(n  9)
Probucol
(n  6)
Vehicle
(n  24)
Probucol
(n  7)
Infraction size (% of circumference) — — 51.57  1.61‡ 49.72  1.5‡
Mean scar thickness (mm) — — 0.33  0.04‡ 0.64  0.07‡§
Scar surface (cm2) 0.21  0.03 0.25  0.00 1.26  0.04 1.16  0.07‡
Mean myocardial wall thickness (mm) 1.84  0.13 1.66  0.11 1.74  0.07 1.617  0.11
Dilation index* 0.38  0.04 0.42  0.03 0.61  0.02‡ 0.60  0.02‡
Cardiac fibrosis† 2.99  0.18 2.26  0.11§ 6.64  0.58‡ 2.68  0.08‡§
ANF 2.67  0.76 2.49  0.56 16.69  1.85‡ 22.05  1.65‡
MHC 2.09  0.69 1.76  1.11 13.68  1.05‡ 10.18  5.07‡
MHC 14.36  1.08 15.87  2.17 6.99  0.85‡ 6.87  1.08‡
SkACT 3.67  0.69 5.48  1.06 14.81  0.93‡ 14.72  1.22‡
*Ventricular cavity area on midleft ventricular cross-section/ventricular area on midleft ventricular cross-section; †collagen
volume density percent; ‡p  0.05 vs. sham or small MI; §p  0.05 vs. vehicle.
ANF  atrial natriuretic factor; MHC  myosin heavy chain; MI  myocardial infarction; SkACT  skeletal actin.
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sociated with preservation of the anti-oxidant capacity of
the heart (10). In the present study, probucol was given in
doses previously shown to be effective as an anti-oxidant
(10) and was demonstrated to normalize the measurement
of cardiac oxidative stress (malondialdehydes) in hearts with
large MIs.
Figure 3. Representative left ventricle midventricular cross-sections (5.3) of a sham-operated rat (A) and rats with large myocardial infarctions (MIs)
treated with vehicle (B) or probucol (C); representative slides of the collage network stained with Sirius red (400) for a sham-operated rat (D); and rats
with large MIs treated with vehicle (E) or probucol (F).
Figure 4. Passive left ventricle pressure-volume relationships of rats with sham-to-small myocardial infarctions (MIs) and large MIs according to treatment group.
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Survival, cardiac oxidative stress and cytokine expres-
sion. We found that probucol resulted in marked improve-
ment in post-MI survival. This improvement was much
greater than any we have documented in our previous
studies of multiple interventions in this model. Why this
occurred remains speculative but most likely results from the
powerful anti-oxidant properties of probucol (10). In this
post-MI rat model, Singal et al. (16) have shown that an
increase in oxidative stress coincides with the appearance of
hemodynamic abnormalities, and Kinugawa et al. (8) dem-
onstrated that the anti-oxidant DMTU preserved post-MI
LV function. Congestive heart failure itself is known to be
associated with an increase in oxidative stress, which is
known to exert a number of deleterious effects that can lead
to further progression of heart failure and an increased risk
of death (3,4). The deleterious effects associated with
oxidative stress include direct cellular toxicity, degradation
of collagen matrix and decreased myocardial contractility
(3–5).
In addition, oxidative stress is a powerful stimulant for
the increased expression of pro-inflammatory cytokines (4),
which of themselves can result in further myocardial depres-
sion, adverse ventricular remodeling, direct cytotoxicity and
further oxidative stress (16). In this study, we documented a
lack of increase in TNF- but a persistent increase in IL-1
four weeks after MI in the vehicle group, a finding consis-
tent with the results of Ono et al. (17) eight weeks after MI.
Probucol reduced the cardiac expression of two inflamma-
tory cytokines (IL-1 and IL-6) that are known to be
cardiotoxic and to have a negative inotropic effect (16).
Because of the dynamic nature of post-MI cardiac cytokine
activation, particularly early after MI, it is also possible that
a probucol-induced reduction in cardiac cytokine expression
early after MI contributed to its early beneficial effects.
Finally, both oxidative stress and cytokines are powerful
stimuli for apoptosis, which can result in further cardiac
compromise as post-MI LV dysfunction develops (16,17).
Probucol may have improved post-MI survival by reduc-
ing ventricular arrhythmias. Early and late post-MI mortal-
ity in this model have been shown to be largely the result of
ventricular arrhythmias (18). Global LV remodeling was
not different in probucol-treated rats after MI, but probucol
Figure 5. Cardiac expression of inflammatory cytokines (A) and cardiac oxidative stress (B). IL  interleukin.
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may have had indirect anti-arrhythmic effects by reducing
cardiac fibrosis, which has been associated with an increased
susceptibility to ventricular arrhythmias (19). In a rabbit
ischemia-reperfusion model, probucol has been shown to
reduce ventricular arrhythmias and myocardial stunning
(20). Judging from the results of this study, the QT interval
prolonging effects of probucol did not appear to adversely
affect survival (21).
Cardiac function. Long-term treatment with probucol
resulted in improved systolic LV function. Reduced cardiac
expression of the pro-inflammatory cytokines IL-1 and
IL-6 may have contributed to improved LV systolic func-
tion because both of these cytokines are known to reduce
cardiac contractility. Prevention of excessive cardiac fibrosis
may also have helped because an increase in cardiac fibrosis
is associated with both systolic and diastolic dysfunction
(22). Finally, the improvement of in vivo systolic ventricular
function with probucol could have at least partially resulted
from probucol-induced preservation or even enhancement
of cardiac -adrenergic responsiveness, HR having been
preserved or even increased with probucol despite a large
MI. Oxygen free radicals are known to induce -adrenergic
receptor down-regulation and post-receptor abnormalities
that are reversed by anti-oxidants (23). One mechanism that
did not contribute to improved LV function is a modifica-
tion of fetal gene expression. This lack of effect also suggests
that oxidative stress is not involved in the process that
translates the genotypic characteristics to the functional
state of the myocardium.
The apparent probucol-induced increase in LVEDP in
vivo is hard to explain. This is particularly true, considering
the reduction in cardiac fibrosis with probucol and the lack
of difference in the passive diastolic pressure-volume rela-
tionship between the two MI groups. Part of the explana-
tion could be related to the greater HR and, thus, decreased
ventricular filling time and/or the greater afterload of these
hearts. Another possibility is greater LV hypertrophy with
probucol, although this difference in LVW did not persist
when adjusted for BW. In addition, a direct or indirect
effect of probucol on cardiac relaxation or fluid retention
cannot be ruled out.
Comparison with DMTU. Significant differences between
the effects of the anti-oxidant probucol and the reported (8)
effects of the hydroxyl radical scavenger DMTU on ventric-
ular remodeling were noted. In the Kunigawa et al. study,
DMTU attenuated ventricular dilation, reduced cardiac
hypertrophy, reduced cardiac fibrosis, but did not modify
scar thickness; while in our study, probucol did not modify
ventricular dilation, did not reduce cardiac hypertrophy (and
may even have increased it), but reduced cardiac fibrosis and
increased scar thickness. This resulted in better preservation
of LV function with DMTU, a decrease in LVEDP rather
than the increase with probucol, and a reduction in lung
weight—a finding not found with probucol. Why this
difference between these two agents should occur is specu-
lative but may result from the earlier post-MI introduction
of DMTU (6 h vs. 24 h for probucol), a period when large
amounts of free radicals are known to be present. Alterna-
tively, the difference may be the result of more effective
suppression of oxygen free radicals with DMTU. In any
case, these two studies taken together strongly support an
important deleterious role for post-MI oxidative stress and
suggest that further exploration of the post-MI therapeutic
use of these agents is warranted.
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